Head to head
Medtronic vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: MDT · ABT
MDT
Medtronic
85.51-1.81%
1-year price shape — -11% over the period
Quant Rating D · 27/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Medtronic edges it on the scoreable measures. Medtronic has the highest Quant Rating (27); Medtronic has done best over the past year (-11%); Medtronic trades cheapest on trailing earnings.
| MDT | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 85.51 | 98.73 |
| Change today | -1.81% | +0.58% |
| 1-year return | -10.9% | -24.1% |
| Market cap | $109.38B | $170.84B |
| 52-week range | 72.06 – 102.92 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | 21.06 | 31.95 |
| P/E percentile, own 5-yr range | 5th | 62nd |
| P/B | 2.18 | 3.34 |
| Dividend yield | 3.33% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | 3.73 | 3.72 |
| Net profit (TTM) | $4.77B | $6.44B |
| Revenue (TTM) | $37.54B | $46.59B |
| Revenue growth (YoY) | +13.7% | +13.0% |
| Gross margin | 65.0% | 56.6% |
| Operating margin | 19.0% | 15.8% |
| Net margin | 13.9% | 11.6% |
| Free cash flow (TTM) | $6.13B | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 87.6% | 81.2% |
| Insider activity (12mo) | 28 buy / 17 sell | 36 buy / 12 sell |
| Short interest (% of float) | 1.3% | 1.1% |
| Analyst consensus | 60% buy / 40% hold (20) | 100% buy (14) |
| Analyst price target | $103 (+21%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | D (27) | E (15) |
| Company | ||
| Employees | 95,000 | 115,000 |
| Founded | 2014 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.